The criteria described in this manuscript enabled rapid and efficient ART initiation across a diverse network of thirty participating clinical research sites in six countries.
MHRP, with Walter Reed Army Institute of Research (WRAIR) and the Henry M. Jackson Foundation (HJF), was selected by the National Institute of Allergy and Infectious Diseases (NIAID) at National Institute of Health as a Clinical Trial Unit (CTU) for their HIV research networks for the next seven years.
The Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM), through a sub-recipient contract under the National Agency for the Control of HIV/Aids (NACA), selected the MHRP/HJFMRI Ltd. Gte Nigeria team to develop national guidelines for key population services. The award will allow the MHRP Nigeria team to help develop national guidelines for key population (KP) services.
Each year in Tanzania, 51 of every 100,000 women die from cervical cancer. With limited access to cervical cancer screenings and treatment services, only around 20% of those with the disease will survive after 5 years of diagnosis. Women living with HIV are at a higher risk of getting the disease. They are also at a higher risk of the disease progressing to a more severe form as well as death. Fortunately, with regular cervical screenings, early changes can be treated.
Thousands of voices joined together in song as MHRP partners in Mbeya City, Tanzania, hosted the first ever DREAMS program graduation, where 1,804 adolescent girls and young women (AGYW) celebrated their completion of the core DREAMS training.
The DREAMS initiative is funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and implemented through the Henry Jackson Foundation Military Research International (HJFMRI) and local partners in Africa. DREAMS aims to help young women become Determined, Resilient, Empowered, AIDS-free, Mentored and Safe through education, vocational training and other evidence-based interventions.
In a new preclinical study conducted by MHRP, an HIV vaccine formulated with a novel adjuvant called AFLA developed at the Walter Reed Army Institute of Research elicited stronger immune responses than a vaccine with a more commonly used alum adjuvant. Findings from the study were published in PLOS Pathogens.
